Ftorafur, adriamycin, cyclophosphamide and bcg in the treatment of metastatic breast cancer
Why the study?
Does ACFTOR-BCG improve response rates or decrease toxicity compared to FAC-BCG in patients with metastatic breast cancer?
Population
91 evaluable patients with metastatic breast cancer
Comparison
Ftorafur, Adriamycin, cyclophosphamide, and BCG vs 5-FU, Adriamycin, cyclophosphamide, and BCG
Design
Cohort
Authors
Discussion
Loading...
Member takes
Implication
Comparable responses in this cohort do not support regimen change; leaves open randomized trials to evaluate efficacy and toxicity.
Structured PICO
Does ACFTOR-BCG improve response rates or decrease toxicity compared to FAC-BCG in patients with metastatic breast cancer?
P
Population
91 evaluable patients with metastatic breast cancer
I
Intervention
Ftorafur, Adriamycin, cyclophosphamide, and BCG (ACFTOR-BCG)
C
Comparator
5-FU, Adriamycin, cyclophosphamide, and BCG (FAC-BCG) (historical control)
O
Outcome
Overall objective response ratesurrogate
The combination of Ftorafur, Adriamycin, cyclophosphamide, and BCG did not offer any advantages in effectiveness or reduced toxicity over the FAC-BCG regimen for metastatic breast cancer, but caused substantial neurological and gastrointestinal toxicity.
Cite This Study
Hortobágyi et al. (1979) studied this question.